Amerise Biosciences Limited (BOM:531681)

Amerise Biosciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	0.06	-1.46	-1.19	5.49	-3.37
Other Operating Activities	0.02	-0	-	-	-
Change in Accounts Receivable	-	-	62.17	-62.17	-
Change in Accounts Payable	-	-	-62.66	57.85	-
Change in Other Net Operating Assets	30.63	-0.23	0.36	-0.56	-0.57
Operating Cash Flow	30.71	-1.69	-1.32	0.61	-3.94
Investment in Securities	-1.16	23.01	1.26	-16.51	23.3
Investing Cash Flow	-30.7	2.67	1.26	-1.51	3.89
Short-Term Debt Issued	-	-	0.07	0.83	-
Total Debt Issued	-	-	0.07	0.83	-
Short-Term Debt Repaid	-	-0.9	-	-	-
Total Debt Repaid	-	-0.9	-	-	-
Net Debt Issued (Repaid)	-	-0.9	0.07	0.83	-
Financing Cash Flow	-	-0.9	0.07	0.83	-
Miscellaneous Cash Flow Adjustments	-	-	-0	0	-
Net Cash Flow	0.01	0.08	0.01	-0.06	-0.06
Levered Free Cash Flow	30.7	-1.14	-1.17	-1.44	-2.68
Unlevered Free Cash Flow	30.7	-1.14	-1.17	-1.44	-2.68
Change in Net Working Capital	-30.65	0.23	0.13	4.88	0.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.